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ABSTRACT
Immune reconstitutionmay differ following cord blood transplantation (CBT) and bonemarrow transplantation
(BMT), and this may lead to a difference in varicella zoster virus (VZV) disease rates. One hundred fourteen
VZV seropositive children received a CBT (37 patients), or a T-replete BMT (77 patients) at our institution.
Patients did not received specific VZV disease prophylaxis. VZV disease was diagnosed by immunofluorescence
or culture in 41 (36%) patients. In multivariate analysis, VZV disease was more frequent in older children (rel-
ative risk [RR] 1.11 per year; 95% confidence interval [CI], 1.04-1.18; P 5 .002), and after CBT (RR 2.27; 95%
CI, 1.18-4.34; P5 .013). The cumulative incidence of VZV disease at 3 years posttransplant was 46% following
CBT. VZV disease incidence was 71% in CBT patients over 10 years old at transplant. Visceral dissemination
occurred in 7 patients (6 CBT and 1 BMT) (P5 .005). VZV disease is thus more frequent and more severe after
CBT than after BMT.
 2008 American Society for Blood and Marrow Transplantation
KEY WORDS
Cord blood transplantation  Varicella-zoster virus  Immune reconstitution
Biology of Blood and Marrow Transplantation 14:867-871 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1408-0001$32.00/0
doi:10.1016/j.bbmt.2008.05.006INTRODUCTION
Varicella zoster virus (VZV) disease incidence after
hematopoietic stem cell transplantation (HSCT)
ranges from 25% to 67%. Hospitalization is frequently
needed for the administration of intravenous acyclovir.
Neuralgia is frequent, and may impair quality of life.
Severe complications may also occur, such as myelitis
and ocular involvement. Secondary infections or dis-
seminated disease can even cause death [1-7].
Several risk factors for VZV disease after HSCT
have been described: older age, irradiation in the
conditioning regimen, allogeneic transplantation,
HLA-mismatched transplantation, extensive chronic
graft-versus-host disease (GVHD), and seropositive
status for VZV before transplantation [1-3,5]. Unex-
pectedly, acute GVHD (aGVHD) has been reported
to be associated with a lower incidence of VZV disease
[4,7].Although it has been reported that the incidence of
serious infections is similar after BMT and CBT [8],
no study has specifically compared VZV disease after
CBT and BMT. In 1 study comparing all serious infec-
tions, severe VZV disease was infrequent in both
groups, but several patients received high-dose pro-
phylactic acyclovir [8]. The rate of VZV disease rate
was unexpectedly high (80%) in a series of adult pa-
tients after CBT, but no control group was available
[4]. We therefore studied the incidence of VZV disease
in 114 consecutive VZV seropositive patients receiving
CBT or T-replete BMT without specific VZV
prophylaxis.
PATIENTS AND METHODS
Patients
Data on all VZV seropositive patients who
underwent a first allogeneic HSCT at the CHU867
868 K. Vandenbosch et al.Sainte-Justine between January 1996 and December
2003 were obtained using the HSCT research database
and patient medical charts after IRB approval. The
conditioning regimen included total-body irradiation
(TBI) or busulfan, except for patients with severe
aplastic anemia. Grafts were not T cell depleted.
GVHD-prophylaxis included cyclosporin A (CsA)
and a short course of methotrexate (MTX) after
BMT. Fifteen CBT patients received CsA and MTX,
then 7 subsequent patients received CSA, MTX, and
methylprednisolone (MP), and finally 15 received
CsA and MP. Patients who received an unrelated
CBT or BMT were given 2 mg/kg antithymocyte
globulin (Thymoglobulin, Sangstat) on days 22, 21,
11, and 12. Supportive care has been described else-
where, and was identical for all patients, excepted for
granulocyte-colony stimulating factor (G-CSF),
which was administered only after CBT [9]. Notably,
patients did not receive any prophylaxis against VZV
reactivation. Weekly intravenous immunoglobulin
(500 mg/kg) was administered to all patients from
transplant to day 1100, then monthly for 6 months.
Specific anti-VZV immunoglobulin was administered
to all patients in contact with VZV disease. Patients
with a pretransplant positive serology for herpes sim-
plex virus were given acyclovir 250 mg/m2/12 hours
from day 21 to day 121. A preemptive strategy was
used for CMV control, based on weekly PCR and
the use of gancyclovir. CD41, CD81, CD191, and
CD161561 lymphocytes counts were determined by
flow cytometry after 1, 3, 6, 9, and 12 months.
Definition of VZV Serology and Disease
The VZV serostatus of recipients prior to trans-
plantation was determined by enzyme assay (Enzyg-
nost, Behring, Marburg, Germany). VZV disease was
suspected by the appearance of typical cutaneous vesic-
ular lesions, and confirmed by virus isolation using
standard viral cultures or antigen detection by direct
immunofluorescence. Visceral organ dissemination
was defined as histologic or culture evidence of inter-
nal organ involvement or clinical evidence of organ in-
volvement in the absence of other identified causes
[3,7]. Isolated liver enzyme elevation was not consid-
ered a symptom of visceral organ dissemination [7].
Statistical Methods
Only the first VZV disease occurrence was consid-
ered for statistical calculations. A multivariate propor-
tional hazard model was used to determine the effect of
stem cell source (CBT versus BMT), age (as a continu-
ous variable), TBI, and GVHD on the risk of VZV dis-
ease. Variables were considered significant at a .05
level. The cumulative incidence of VZV disease was
calculated per stem cell source, adjusting for the com-
peting risks of second transplant and death. Statisticalcalculations were done using SPSS 11.0 and NCSS.
CD41, CD81, and CD561 cell reconstitution was
compared at 1, 3, 6, 9, and 12 years posttransplant by
the nonparametric Mann-Whitney test.
RESULTS
Incidence of VZV Disease
Between January 1996 and December 2003, 133
consecutive patients\21 years old received a first allo-
geneic CBT or BMT at CHU Sainte-Justine. Nine-
teen patients were seronegative for VZV and thus
excluded form analysis. One hundred fourteen patients
were seropositive for VZV before transplant. Thirty-
seven patients received a CBT, and 77 patients
a BMT. VZV disease was diagnosed by immunofluo-
rescence or culture in 41 (36%) patients. VZV disease
frequency was identical after related and unrelated
BMT (27% versus 31%). Cumulative incidence of
VZV disease was 46% at 3 years in the CBT group,
and 31% in the BMT group (Figure 1).
Risk Factors for VZV Disease in Multivariate
Analysis
CBT patients differed from BMT patients in char-
acteristics known to modify VZV disease probability:
they were younger and radiation was used less fre-
quently in their conditioning regimen. These 2 differ-
ences may have reduced the risk of VZV disease in our
CBT patients. Conversely, they experienced fewer ep-
isodes of aGVHD, thereby possibly increasing their
risk of VZV disease (Table 1). To take these differ-
ences into account, multivariate analysis was used to
determine the impact of stem cell source, age at trans-
plantation, aGVHD, and radiation in the conditioning
regimen on VZV disease. Stem cell source and age at
transplant were found to be significant predictors of
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Figure 1. Time to VZV disease according to stem cell source. VZV
disease was more frequent after cord blood transplantation than after
bone marrow transplantation.
Varicella-Zoster Virus after Cord Blood Transplantation 869VZV disease. VZV disease was more frequent in older
patients (relative risk [RR] 1.11 per year; 95% confi-
dence interval [CI], 1.04-1.18; P 5 .002) and in CBT
recipients (RR 2.27; 95% CI, 1.18-4.34; P 5 .013).
Frequency of VZV disease in each age group in shown
in Figure 2. When restricted to patients older than 10
years at transplant, cumulative incidence of VZV
disease was 71% after CBT.
Disseminated VZV Disease
Visceral dissemination occurred in 1 BMT patient
and in 6 CBT patients (P5 .005). Age at transplant of
the 6 CBT patients with visceral dissemination ranged
from 7 to 16 years. All 6 were transplanted for malig-
nant diseases and 2 experienced GVHD. Disseminated
VZV disease occurred shortly after transplantation
(median: 2.4 months posttransplant; range 1.8-10
Table 1. Patients’ Risk Factors for Varicella Zoster Disease
Cord Blood Bone Marrow
Number of patients 37 77
Gender Male 25 (68%) 44 (57%)
Age at transplantation (median) 7.4 years 10.1 years
Range (1 months
to 17 years)
(5 months
to 21 years)
Donor type
Related 2 (5%) 55 (71%)
Unrelated 35 (95%) 22 (29%)
Radiation in the conditioning 21 (57%) 54 (70%)
Acute Grade 2 to 4 GVHD 7 (19%) 25 (32%)
Extensive chronic GVHD 2 (5%) 5 (6%)
Bone marrow
Age at transplant (years)
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Figure 2. VZV disease and age at transplantation after cord blood
and bone marrow transplantation. Number of patients in each age
group experiencing VZV disease (black bars) after cord blood (upper
panel) and bone marrow transplantation (lower panel).months). VZV disease involved the liver (3 patients),
intestines (4), lungs (2), pancreas (2), and kidneys (1).
Four out of 6 died (3 from other infections, 1 from leu-
kemia relapse). None of the deaths was directly related
to VZV disease.
Immune Reconstitution
As VZV is controlled by the immune system, dif-
ferences in immune reconstitution may explain the ob-
served differences in VZV incidence after CBT and
BMT. We thus compared the reconstitution at differ-
ent time points (1, 3, 6, and 12 months) of CD41,
CD81, and CD561 cells (Figure 3). As all our patients
received the same regimen of intravenous immuno-
globulins, we did not expect that a difference in hu-
moral (B cell) immune reconstitution would have any
impact on VZV disease. Thus, B cell reconstitution
was not compared. To account for multiple compari-
sons, the significance level for each individual compar-
ison was set to 0.01. Number of blood CD41 cells was
significantly lower 1 month after CBT. Number of
blood CD81 cells was significantly lower 1, 3, 6, and
9 months after CBT. In contrast, number of CD561
cells was higher 1 and 3 months after CBT.
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Figure 3. CD41, CD81, and CD561 cell reconstitution after cord
blood (blank circles) and bone marrow (filled triangles) transplanta-
tion. Each circle or triangle represents a patient. Cell counts were
compared, using a .01 significance level to account for multiple
comparisons. Significant P values are reported.
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This study is the first comparison of VZV disease
incidence and severity after CBT and BMT in the ab-
sence of specific VZV prophylaxis. It shows that VZV
disease is more frequent after CBT, with a cumulative
incidence of 46% at 3 years posttransplant and RR of
2.27. Age at transplant is also a risk factor for VZV dis-
ease, leading to a 71% cumulative incidence of VZV
disease in CBT patient over 10 years at transplant. Dis-
seminated VZV disease occurred in 6 CBT patients
(35% of CBT patients with VZV disease), and only
in 1 (4%) BMT patient.
In our multivariate analysis, the use of irradiation
in the conditioning regimen was not associated with
a higher incidence of VZV disease. Data from the lit-
erature concerning this association are conflicting. A
previous study found that irradiation in the condition-
ing regimen was associated with a higher incidence of
VZV in multivariate analysis [1]. In a more recent
study conducted on 310 patients, multivariate analysis
showed that this association only approached signifi-
cance (P 5 .06) [7]. Two other studies did not find
any significant association between irradiation in the
conditioning regimen and VZV disease [2,3]. It is,
therefore, difficult to conclude from these data
whether irradiation in the conditioning regimen in-
creases the risk for VZV disease after HSCT.
The frequency of VZV disease is particularly high
in older patients. Our data are in line with the previous
observation of an incidence of 80% of VZV disease af-
ter CBT in adults [4]. This higher frequency may be
explained by the slower immune reconstitution of
older children and adults. Younger patients may also
have passively acquired anti-VZV immunoglobulins
of maternal origin. Some of our younger patient might
thus have been enrolled in the study, although they had
never encountered VZV, and therefore have no risk of
posttransplant reactivation. However, it has been re-
ported that antibodies against VZV of maternal origin
disappeared after 6 to 9 months of life [10,11]. Thus,
almost all our younger CBT patients were indeed at
risk of VZV disease.
The difference in VZV disease incidence between
BMT and CBT in our cohort is not explained by a dif-
ference in GVHD prophylaxis, unrelated transplant
frequency, or VZV prophylaxis. First, when the
BMT patients were compared with the CBT patients
with the same GVHD prophylaxis (CsA and MTX),
the difference was unchanged: 10 out of 15 (66%) pa-
tients experienced VZV disease after CBT, compared
with 31% in the BMT group. Second, all CBT patients
received an unrelated transplant and Thymoglobulin,
whereas some BMT patients received a related trans-
plant. The patients with a related BMT were not given
Thymoglobulin. The administration of Thymoglobu-
lin and the unrelated nature of the graft may haveplayed a role in the higher frequency of VZV after
CBT. Arguing against this hypothesis is the observa-
tion that this was not the case in our BMT patients,
as the incidence of VZV disease after unrelated and re-
lated BMT was similar (27% versus 31%). This obser-
vation is in line with a previous study that
demonstrated that Thymoglobulin in the conditioning
regimen did not impact the risk of posttransplant VZV
disease [7]. Finally, the frequency of treatments that
may control VZV was the same for both groups: 3
weeks of acyclovir for HSV prophylaxis, therapeutic
use of acyclovir for HSV disease, or preemptive use
of gancyclovir for CMV (data not shown).
Our data thus strongly suggest that the difference
in VZV disease frequency and severity is because of
the stem cell source. This difference is probably re-
lated to differences in immune reconstitution. First,
immune reconstitution after CBT is characterized by
a delay in CD81 cell reconstitution [12,13]. CD81
cell reconstitution was indeed delayed in our CBT
group, with a median of 98  106/L at 9 months post-
transplant, compared with 302  106/L in the BMT
group. Of note, VZV disease frequency in CBT pa-
tients was higher despite a faster early NK cell recon-
stitution, suggesting that NK cell does not play
a prominent role in VZV control in the setting of he-
matopoietic transplantation. Second, cord blood T
cells never encountered VZV. This absence of previ-
ous priming may explain a lack of VZV control ob-
served in CBT patients.
Our study shows that VZV disease is more fre-
quent and more severe after CBT. VZV prophylaxis
must therefore be considered in these patients, at least
for the first year after transplant [5]. However, this
strategy has been shown to reduce VZV disease inci-
dence only during prophylaxis administration, as
VZV incidence at 4 years posttransplant is not modi-
fied by a 1-year VZV prophylaxis [5]. If cord blood
T cell naivety is the correct explanation of the higher
VZV disease frequency after CBT, one must expect
that prophylaxis will only delay but not suppress
VZV disease occurrence after CBT. Innovative strate-
gies are thus needed to reduce VZV disease burden
after CBT. These strategies will have to combine anti-
viral prophylaxis and immunization [14]. Antiviral
prophylaxis could be stopped after successful immuni-
zation. However, immune reconstitution and response
to VZV immunization differs from patient to patient
[15]. To define the optimal length of VZV prophylaxis
after immunization, new strategies are needed to mon-
itor these patients’ immune response to VZV.
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